Life Sciences

Scrutiny of Vytorin marketing continues

Pharma Compliance Alert, November 12, 2008

The Department of Justice (DOJ) and 35 state attorneys general are investigating how Merck and Schering-Plough marketed their combination cholesterol drug Vytorin, according to a Merck filing with the Securities and Exchange Commission.

Post a Comment

Name:

 

E-mail:

 

Please enter your comment below:

   

Please enter the text below:

   
   

Most Popular